Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Bacterium Evaluated as Potential Multiple Sclerosis Trigger

By LabMedica International staff writers
Posted on 06 Nov 2013
A bacterium has been identified that may trigger multiple sclerosis (MS), a chronic, debilitating disorder that damages myelin forming cells in the brain and spinal cord.

Clostridium perfringens type B, an epsilon toxin-secreting bacillus, has been isolated for the first time from a young woman at clinical presentation of MS with actively enhancing lesions on brain seen by magnetic resonance imaging (MRI).

A scientific team from Weill Cornell Medical College (New York, NY, USA) tested banked blood and spinal fluid (CSF) from both MS patients and healthy controls for antibody reactivity to the epsilon toxin (ETX). More...
Western blots were performed using human sera or CSF as the primary antibody. They found that levels of epsilon toxin antibodies in MS patients were 10 times higher than in the healthy controls, as the blood of only one out of 100 control participants showed an immune reaction to the toxin.

The team also examined stool samples from both 30 MS patients and 31 healthy controls enrolled in a clinical study. The mean age of healthy controls was 46.7 years and the mean age of MS subjects was 42.0 years. Of the healthy controls, 14 of 31 were female, and of the MS subjects, 22 of 30 were female. The investigators found that 52% of healthy controls carried the C. perfringens A subtype compared to 23% of MS patients. For CSF, 6 of 62 MS patients, and 1 of 40 controls, were positive for ETX immunoreactivity. For the analysis of sera, 6 of 56 MS patients, and none of the 60 controls were seroreactive to ETX.

Timothy Vartanian, MD, PhD, a professor of neurology and neuroscience, said, “While it is clear that new MS disease activity requires an environmental trigger, the identity of this trigger has eluded the MS scientific community for decades. Work is underway to test our hypothesis that the environmental trigger for MS lays within the microbiome, the ecosystem of bacteria that populates the gastrointestinal tract and other body habitats of MS patients.” 

Professor Vartanian added, “We are also investigating the possibility of developing small-molecule drugs that prevent the toxin from binding to its receptor. But one of my favorite approaches is development of a probiotic cocktail that delivers bacteria that compete with, and destroy, C. perfringens types B and D. It would be such a beautiful and natural way to treat the gastrointestinal system and solve the problem. We are also starting to work on this approach.” The study was published on October 16, 2013, in the journal Public Library of Science ONE.

Related Links:

Weill Cornell Medical College 



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.